Options for Patients with Mantle Cell Lymphoma Are ‘Exploding’, According to One Expert

Mantle cell lymphoma (MCL) is a rare, typically aggressive form of non-Hodgkin lymphoma (NHL) that accounts for approximately 6% of all new cases of NHL in the United States in a given year. But thanks to a research boom in the treatment of the disease, “outcomes are getting better all the time”, according to Dr. Lori A. Leslie.

In an interview with OncLive, CURE’s sister publication, Leslie, an oncologist with the John Theurer Cancer Center, explained that because of this rapid expansion, much of the older information patients have access to is outdated and not indicative of the current treatment landscape.


CURE: Combining science and humanity to make cancer understandable.